Russell Investments Group
ADCT icon

Russell Investments Group’s ADC Therapeutics ADCT Stock Holding History

Russell Investments Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Buy
286,604
+31,695
+12% +$92.5K ﹤0.01% 3012
2026
Q1 		$956K Buy
254,909
+230,377
+939% +$908K ﹤0.01% 2233
2025
Q4 		$86.6K Sell
24,532
-7,970
-25% -$32.3K ﹤0.01% 3093
2025
Q3 		$130K Buy
32,502
+7,701
+31% +$24.3K ﹤0.01% 2950
2025
Q2 		$66.5K Sell
24,801
-14,887
-38% -$31.3K ﹤0.01% 2917
2025
Q1 		$56K Buy
39,688
+22,894
+136% +$38.9K ﹤0.01% 2885
2024
Q4 		$33.4K Buy
16,794
+9,248
+123% +$24.2K ﹤0.01% 2913
2024
Q3 		$23.8K Buy
+7,546
New +$23.8K ﹤0.01% 2925
2023
Q1 		– Sell
-17,800
Closed -$68.4K – 3284
2022
Q4 		$68.4K Buy
+17,800
New +$71.2K ﹤0.01% 2713

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Russell Investments Group's ADCT Position: Q2 2026 in Review

Russell Investments Group increased its ADC Therapeutics (ADCT) stake by 12% in Q2 2026, buying an estimated $92.5K and bringing the position to 286,604 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #3012.

Russell Investments Group first reported a position in ADCT in Q4 2022 and has held it in 9 quarters since. The position peaked at $956K in Q1 2026. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Russell Investments Group held 286,604 shares of ADC Therapeutics worth $307K as of Q2 2026.
  • Russell Investments Group bought 31,695 ADC Therapeutics shares in Q2 2026, an estimated $92.5K.
  • ADC Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3012 holding.
  • Russell Investments Group first reported a position in ADC Therapeutics in Q4 2022 and has held it in 9 quarters since.
  • Russell Investments Group's ADC Therapeutics position peaked at $956K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.